F-star Therapeutics, Inc.: invoX Pharma and F-star Therapeutics issue Joint Statement

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK), and F-star Therapeutics, Inc. ("F-star")

Related Keywords

London ,City Of ,United Kingdom ,Julia Bradshaw ,John Fraunces ,Rob Winder ,Sam Purewal ,Committee On Foreign Investment ,Company Annual Report On Form ,Lifesci Advisors ,Therapeutics Inc ,Sino Biopharmaceutical Limited Biopharm ,Company Quarterly Reports On Form ,Nasdaq ,Sino Biopharmaceutical Limited ,F Star Therapeutics ,Foreign Investment ,United States ,Expiration Date ,Eastern Time ,Merger Agreement ,End Date ,Foreign Investment Condition ,Annual Report ,Quarterly Reports ,Sci Advisors ,Investor Relations ,Star ,Herapeutics ,Invox ,Dharma ,Issue ,Joint ,Statement ,